PHP70 PREVENTABLE HOSPITALIZATIONS AND HEALTH INSURANCE COVERAGE IN HARRIS COUNTY, TEXAS  by Murty, S. et al.
higher than self. Using DBDC questions seems to have additional benefit of refining
open ended questions. These results were higher especially in parametric estima-
tionmodels using only DBDC questions. This observation cautions us of selecting a
specific analytic method may influence the results. CONCLUSIONS: This study is
the first step toward resolution of controversies around economic evaluations of
healthcare in Korea and hopes to encourage more local research on this issue.
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OBJECTIVES: Preventable hospitalizations (PHs) are hospitalizations that can be
avoided with appropriate and timely access to primary care. Lack of health insur-
ance has been associated with frequent PHs in several communities in the U.S. In
Harris County, public and private safety net clinics provide subsidized primary care
to uninsured individuals. Therefore, being uninsured may not result in unneces-
sary hospitalizations. The objective of this study was to determine the prevalence
of PHs and to examine the effect of health insurance on the risk of PHs in Harris
County (Houston), Texas.METHODS:This studywas restricted to non-elderly adult
(age 18 to 64) residents of Harris County, Texas. The Agency of Healthcare Research
and Quality (AHRQ) guidelines were used to identify a hospitalization as prevent-
able or not from the Texas Health Care Information Collection inpatient discharge
data – 2007. Prevalence wasmeasured as the rate of PHs; i.e. the number of PHs per
100 hospitalizations. Health insurance status was classified as “uninsured”, “Med-
icaid-insured” or “privately-insured”. A 2-analysis followed by a multivariable
logistic regression controlling for demographic and socioeconomic characteristics
was performed to determine the effect of health insurance on the risk of PHs.
RESULTS: There were 17,810 PHs among non-elderly adults in Harris County in
2007 (PH rate  7.83 PHs per 100 hospitalizations). Health insurance status was
significantly associated with PHs (2781.83; p0.001). In themultivariable model,
the uninsured had 60% higher odds of having a PH (OR1.628; p0.001) as com-
pared to the privately insured. Medicaid-insurance was also associated with a
marginally higher risk of PHs (OR1.065; p0.05). CONCLUSIONS: Lack of health
insurance is an important factor in determining risk of PHs in Harris County, de-
spite the presence of safety net clinics. If recent healthcare reforms are successful
in increasing health insurance coverage, a large proportion of these unnecessary
hospitalizations may be avoided.
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OBJECTIVES: To assess impact of the Medicare Part D coverage gap on prescription
drug utilization andmedication adherence using data fromMedicare beneficiaries
enrolled in a large health plan in New Mexico in 2007. METHODS: Quasi-experi-
mental, retrospective, pre-post with control group study design was utilized. Pre-
and post-coverage gap prescription drug utilization and medication adherence of
beneficiaries enrolled in a health plan with no prescription drug coverage during
the coverage gap (no coverage plan) was compared with generic drug coverage
(generic coverage plan) and full prescription drug coverage (full coverage plan) plan
beneficiaries. Prescription drug utilization was assessed using total number of pre-
scriptions per member. Medication adherence was measured using Medication
Possession Ratio and the Proportion of Days Covered (PDC). Difference-in differ-
ence analysis (DiD) was used to compare pre- and post-coverage gap prescrip-
tion drug utilization and medication adherence between the three plans.
RESULTS: Of the 14,846 beneficiaries who met inclusion and exclusion criteria,
2,661 (17.92%) entered the coverage gap in 2007. DiD analyses indicated that
beneficiaries in the no coverage plan filled significantly fewer prescriptions in
the post-coverage gap period, than beneficiaries in the full (14.67 fewer prescrip-
tions; p0.001) and generic (12.52 fewer prescriptions; p0.001) coverage plans.
Significant decrease in post-coverage gap medication adherence was observed
between no coverage and full coverage plan beneficiaries with respect to statins
(5.8%), ARBs (16%) and PPIs (18.1%). Significant decrease in post-coverage gap
medication adherence was observed between no coverage and generic coverage
plan beneficiaries utilizing statins (1.1%) and ARB’s (12%). No significant differ-
ences were observed between full and generic coverage plan beneficiaries. Sig-
nificant differences in adherence were found only when adherence was mea-
sured using the PDC. CONCLUSIONS: Lack of prescription drug coverage during
the Medicare Part D coverage gap may lead to decreased utilization and adher-
ence to certain classes of prescription drugs.
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OBJECTIVES: The aim of the study was to evaluate the quality of pharmacoeco-
nomic studies based in India.METHODS: A literature search was conducted using
PubMed, Medline, EconLit, PsycInfo and Google Scholar to identify published work
on pharmacoeconomics studies based in India. Original research studies that eval-
uated pharmaceuticals, and were conducted between 1990 and 2010 in India were
included. Two reviewers independently reviewed the articles using a subjective
10-point scale (10 being the highest) and the 100-point ‘Quality of Health Economic
Studies’ (QHES) questionnaire (100 being the highest). RESULTS: The included ar-
ticles (n29) were published in 23 different journals. Only 9 articles were published
in journals based in India. The first article was published in 1998. Each article was
written by an average of five authors. Themajority of authors resided in India (62%)
at the time of publication and had a medical background (90%). Cost-effectiveness
analysis was the most frequently used method of analysis (79%). The source of
funding and study perspective was not listed in 45% and 41% of the studies respec-
tively. The study design was a randomized controlled trial for 41% of the studies.
The mean subjective quality score of all the articles (n  29) was 7.8 (SD1.3) and
the mean QHES scores for the studies evaluating costs and outcomes (n  24) was
86 (SD6). The quality score was significantly (p0.05) related to country of resi-
dence of primary author (non-Indiahigher) and the study design (randomized
controlled trialshigher). CONCLUSIONS: The need for economic evaluation of
pharmaceuticals is imperative, especially in developing countries like India; be-
cause it can help decisionmakers allocate scarce resources in a justifiablemanner.
Standardization of guidelines, and improved pharmacoeconomic education -start-
ing from the undergraduate level to specialization - are two suggestions to help to
improve the quality of the pharmacoeconomic research in India.
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OBJECTIVES: To understand the extent of likely variation if any in underlying
relative efficacy and relative effectiveness of drugs used in one or more of the 27
Member States (MS). METHODS: A systematic literature review of studies in four
databases was conducted for the period January 2000 - May 2010: Medline, Embase,
EconLit and Health Management Information Consortium (HMIC). Logical combi-
nations of keywords related to effectiveness, generalisability, external validity,
transferability, Europe and review were searched. RESULTS: A total of 326 articles
were initially identified and ten formed the bases of the review. Nine were
reviews or original cost-effectiveness studies and relevant data on the effective-
ness results was extracted. First, we found that there is a common assumption
in the literature that relative efficacy is constant across countries and therefore
generalisable. Less is known about whether relative effectiveness is indeed
similar or different. Second, we grouped the factors that could potentially in-
troduce variation in relative effectiveness: (i) patients and disease characteris-
tics; (ii) comparators used; (iii) different measures of health outcomes; (iv) vari-
ations in clinical practice. Third, no observational studies were identified.
Evidence from studies using efficacy data, mainly from RCTs, was mixed; three
studies found no differences in clinical outcomes across countries, one study
found differences due to patients’ characteristics and severity and another
study using multilevel analysis found country and patients characteristics ex-
plaining partly the heterogeneity of treatment effects. One review report differ-
ences in clinical practice as one major causes of variations in clinical outcomes
between countries. CONCLUSIONS: The literature was scarce and therefore
more evidence is needed before any statement can be claimed on the existence
of variations in relative effectiveness or efficacy in different countries. Future
collaboration among the MS harmonising methodology, generating data and
sharing patients’ registry data will be crucial to produce this evidence.
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OBJECTIVES: Evidence has recently emerged regarding the presence of investigator
learning curves in the context of clinical trials (i.e., the association between clinical
protocol departures and patient enrollment sequence). We reviewed the literature
to identify factors contributing to clinical trial learning curves and potential im-
pacts of learning curves on outcomes accuracy, patient safety and overall trial
success. METHODS: The PubMed database was searched for studies describing
clinical trial learning curve effects and potential solutions to these effects, using
search term combinations including “clinical trial”, “clinical protocol”, “learning
curve”, and “enrollment sequence”. RESULTS: Learning curve effects were identi-
fied in trials including those for treatment of sepsis (PROWESS and ADDRESS) and
high-risk cardiac disease (VALIANT). Outcomes of these trials potentially resulting
from learning curves included ambiguous treatment benefit, increased adverse
events andmortality, and overall trial failure. Potential contributing factors include
those related to study site (e.g., large multicenter trials; sites with poor enrollment
or previous trial experience; inexperienced staff and high staff turnover), study
protocols (e.g., imprecise or complex protocols), and disease severity. Preventing
such learning curve effects would likely have required extensive trial site and staff
screening and training, as well as improved trial protocol design prior to first pa-
tient enrollment. Clinical trial simulation, a methodology identified in several re-
ports, could potentially address clinical trial learning curves by improving protocol
design and staff competence. This approach, which focuses on human factors
involved in conducting clinical protocols, offers the potential to improve the accu-
racy of measured trial outcomes and decrease the likelihood of premature trial
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